var data={"title":"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/contributors\" class=\"contributor contributor_credentials\">Souha S Kanj, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 16, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Pseudomonas aeruginosa</em>, a gram-negative nonfermenting bacillus, is a much-feared pathogen. The organism is common in the environment, especially in water, even contaminating distilled water [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/1,2\" class=\"abstract_t\">1,2</a>]; it is also an important cause of infections associated with hot tubs and contaminated contact lens solutions [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Considerable attention is paid to <em>P. aeruginosa</em> as a potential pathogen in hospitals because:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is often found in water in sinks and can contaminate respiratory equipment, which can serve as an environmental reservoir, especially in intensive care units</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The organism displays a predilection for infecting immunocompromised hosts, including burn patients</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> is the most serious pathogen causing ventilator-associated pneumonia (VAP)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> strains with resistance to multiple antibiotics have become common in some hospitals and regions</p><p/><p>The epidemiology and pathogenesis of infections due to <em>P. aeruginosa</em> will be reviewed here. The clinical manifestations, diagnosis, and treatment of infections due to this organism are discussed separately. (See <a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa pneumonia&quot;</a> and <a href=\"topic.htm?path=pseudomonas-aeruginosa-bacteremia-and-endocarditis\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa bacteremia and endocarditis&quot;</a> and <a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa skin and soft tissue infections&quot;</a> and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20477480\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> was first isolated from green pus by Gessard in 1882. It is a nonfermentative gram-negative aerobic rod that is ubiquitous in the environment and can be grown on a variety of media. The following features are helpful in confirming its identification on culture plates:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Characteristic sweet, grape-like odor</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elaboration of green pigment (<a href=\"image.htm?imageKey=ID%2F77055\" class=\"graphic graphic_picture graphicRef77055 \">picture 1</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oxidase-positive</p><p/><p>Occasionally, identification by laboratory personnel may be delayed because some isolates lack pigments or produce unusual characteristics such as a &quot;rotten potato&quot; odor [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> is often an opportunistic pathogen, causing infections in patients with physical, phagocytic, or immunologic defects in host defense mechanisms. Historically, <em>P. aeruginosa</em> has been a major burn wound pathogen, a serious cause of bacteremia in neutropenic patients, and the most important pathogen in cystic fibrosis (CF) patients. However, these associations have undergone considerable change, with a shift in the spectrum of the hosts who are now commonly infected by <em>P. aeruginosa</em>.</p><p>According to data reported to the National Healthcare Safety Network (NHSN) in the United States from 2011 to 2014,&nbsp;<em>P. aeruginosa</em>&nbsp;is [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The sixth most common cause of hospital-acquired infections in general (7.3 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The second most common cause of ventilator-associated pneumonia (VAP; 16.5 percent) and the most common multidrug-resistant gram-negative pathogen causing VAP</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The third most common cause of catheter-associated urinary tract infections (10.3 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The fifth most common cause of surgical site infections (5.7 percent)</p><p/><p>It is also a common pathogen worldwide; it was the third most common cause of intra-abdominal infections from 2002 to 2011 and the third most common cause of urinary tract infections from 2009 to 2011 [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/7\" class=\"abstract_t\">7</a>]. </p><p>Patterns of antimicrobial resistance have geographical variation. (See <a href=\"#H1590804377\" class=\"local\">'Prevalence of resistance'</a> below.) </p><p>Apart from causing human infections, <em>P. aeruginosa</em> is also an important plant pathogen, affecting tobacco, tomatoes, and lettuce; it can be found in most fresh water environments, including moist areas in hospitals. </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Neutropenia and burns</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the early 1980s, the role of <em>P. aeruginosa</em> in infections in febrile neutropenic patients has diminished in Western Europe and North America. This organism previously accounted for one-third to one-half of gram-negative bacteremia in these patients, but has become a much less frequent pathogen in this setting. As an example, in a single centered retrospective study from China, <em>P. aeruginosa</em> accounted for only 3.5 percent of all gram-negative bacterial isolates from neutropenic patients with bacteremia [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/8\" class=\"abstract_t\">8</a>]. Similar trends have occurred in burn patients in Europe and North America. <em>P. aeruginosa</em> was the single most important cause of burn wound sepsis and infectious deaths following burns in the past, but there has been a reduction in infections due to this organism since the 1980s. However, this trend has not been universally noted, and <em>P. aeruginosa</em> remains an important cause of gram-negative bacteremia in neutropenic patients in some centers, as in Japan and Spain [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p>The reasons for the above trends are not entirely clear, although the use of empiric antibiotic regimens with antipseudomonal activity may play a role. Furthermore, it is likely that incidence of <em>Pseudomonas</em> infection in subpopulations of patients, such as neutropenic and burn patients, is highly complex and related to acquisition and host factors that are poorly understood. (See <a href=\"topic.htm?path=overview-of-neutropenia-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Overview of neutropenia in children and adolescents&quot;</a> and <a href=\"topic.htm?path=drug-induced-neutropenia-and-agranulocytosis\" class=\"medical medical_review\">&quot;Drug-induced neutropenia and agranulocytosis&quot;</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-unexplained-neutropenia#H1006820\" class=\"medical medical_review\">&quot;Approach to the adult with unexplained neutropenia&quot;, section on 'Mechanisms'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Cystic fibrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>To date, <em>P. aeruginosa</em> remains the most common pathogen isolated from adults with CF [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/11\" class=\"abstract_t\">11</a>]. It is also the most common cause of respiratory failure in CF and is responsible for the deaths of the majority of these patients [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/12\" class=\"abstract_t\">12</a>]. With time, however, its relative prevalence seems to have declined. A retrospective analysis of the data reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) found a significant decrease in overall incidence and prevalence of <em>P. aeruginosa</em> from 2006 to 2012 [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/13\" class=\"abstract_t\">13</a>]. This decreasing trend might be explained by improved infection control and strategies focusing on early eradication of the pathogen. (See <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection#H2457284300\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;, section on 'Pseudomonas aeruginosa'</a>.)</p><p>Acquisition of <em>P. aeruginosa</em> begins early in childhood (median one year) [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/12\" class=\"abstract_t\">12</a>]. It is believed that the organism is initially acquired from environmental sources, but patient-to-patient spread may also occur in clinics and households [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/14,15\" class=\"abstract_t\">14,15</a>]. (See <a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease\" class=\"medical medical_review\">&quot;Cystic fibrosis: Clinical manifestations of pulmonary disease&quot;</a>.)</p><p>Over time, a number of mutations occur in <em>P. aeruginosa</em> in the CF lung environment that promote persistence of the organism. In one study, for example, 11 of 30 CF patients were colonized with a hypermutable strain of <em>P. aeruginosa</em> that persisted for years in most cases; such hypermutable strains were not isolated from patients with acute <em>P. aeruginosa</em> infection who did not have CF [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/16\" class=\"abstract_t\">16</a>]. These hypermutable strains tend to be multidrug-resistant [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/16,17\" class=\"abstract_t\">16,17</a>] and accumulate over time, often with the loss of virulence traits [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/17\" class=\"abstract_t\">17</a>]. Interestingly, these adaptations are associated with reduced organism survival in a typical environmental habitat, such as tap water [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/17\" class=\"abstract_t\">17</a>]. Nonmutated strains with maintained virulence represent a minority of organisms.</p><p>The initial acquisition of <em>P. aeruginosa</em> in the CF lung is with nonmucoid strains and occurs early in life (median one year) [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/12\" class=\"abstract_t\">12</a>]. Over time (median 11 years), there is a transition to a mucoid phenotype that is associated with deterioration in cough scores, chest x-ray scores, and pulmonary function.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Other nosocomial infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> is among the most common causes of VAP and carries the highest mortality among hospital-acquired infections [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/18\" class=\"abstract_t\">18</a>]. This fact has remained unchanged despite infection control policies that have tried to control this serious complication of medical therapy. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults&quot;</a>.)</p><p><em>P. aeruginosa</em> is also an important pathogen in patients with bronchiectasis, many of whom eventually harbor multidrug-resistant <em>P. aeruginosa</em> as their final pathogen.</p><p><em>Pseudomonas</em> is also a frequent cause of nosocomial bacteremia [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/19-21\" class=\"abstract_t\">19-21</a>], wound and urinary tract infections, with occasional involvement of other sites following surgery (eg, gram-negative meningitis, sternal osteomyelitis) [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/22\" class=\"abstract_t\">22</a>]. The role of antibiotics in the proliferation of <em>P. aeruginosa</em> in the hospital has also become clear [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/21,23\" class=\"abstract_t\">21,23</a>].</p><p>Nosocomial outbreaks of <em>P. aeruginosa</em> have occurred as a result of faulty or unclean medical equipment or products, environmental reservoirs, and cross-contamination within the hospital [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/24-26\" class=\"abstract_t\">24-26</a>]. One of the largest outbreaks involved 231 patients in 24 hospitals in Norway; the major clinical manifestations were pneumonia and sepsis [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/24\" class=\"abstract_t\">24</a>]. The cause of the outbreak was contamination of moist mouth swabs. The in-hospital mortality rate was 31 percent, occurring only in patients with severe underlying disease. Contamination of medical equipment may also cause pseudo-outbreaks, as illustrated by a report of isolation of extremely drug-resistant <em>P. aeruginosa</em> from the urine of both hospitalized and ambulatory patients due to contamination of an automated urine analyzer [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/27\" class=\"abstract_t\">27</a>]. These reports highlight the importance of the environmental cleaning component of infection control in preventing such infections. (See <a href=\"topic.htm?path=infection-prevention-general-principles#H708071018\" class=\"medical medical_review\">&quot;Infection prevention: General principles&quot;, section on 'Healthcare environment: Cleaning and disinfection'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Community-acquired infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There has been increasing recognition of <em>P. aeruginosa</em> as a cause of community-acquired infections, including folliculitis (due to hot tubs, whirlpools, or contaminated sponges) [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/3,28,29\" class=\"abstract_t\">3,28,29</a>], pneumonia [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/30\" class=\"abstract_t\">30</a>], puncture wound osteomyelitis [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/31\" class=\"abstract_t\">31</a>], endocarditis in injection drug users [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/32,33\" class=\"abstract_t\">32,33</a>], otitis externa after swimming in fresh water lakes [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/34\" class=\"abstract_t\">34</a>], peritonitis or exit site infection in patients undergoing continuous ambulatory peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/35-37\" class=\"abstract_t\">35-37</a>], and community-acquired bacteremia and pneumonia in patients with AIDS [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/38,39\" class=\"abstract_t\">38,39</a>].</p><p class=\"headingAnchor\" id=\"H1864320089\"><span class=\"h1\">ANTIMICROBIAL RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The fact that <em>P. aeruginosa</em> is both intrinsically resistant to a number of antibiotics and can acquire resistance during therapy assists in bacterial virulence.</p><p>The National Healthcare Safety Network (NHSN) looked at the antibiotic resistance rates of <em>P. aeruginosa</em> isolates according to type of infection from 2011 to 2014 [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H340045430\"><span class=\"h2\">Mechanisms of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of mechanisms of antibiotic resistance in <em>P. aeruginosa</em> have been described. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AmpC beta-lactamase [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/40,41\" class=\"abstract_t\">40,41</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extended-spectrum beta-lactamase [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/42,43\" class=\"abstract_t\">42,43</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Downregulation of the outer membrane protein OprD, a carbapenem-specific porin [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/44,45\" class=\"abstract_t\">44,45</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multidrug efflux pumps [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/46-50\" class=\"abstract_t\">46-50</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ability of the organism to form a biofilm [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/51,52\" class=\"abstract_t\">51,52</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible transfer of a 16S rRNA methylase gene from Actinomycetes [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/53\" class=\"abstract_t\">53</a>]</p><p/><p>Acquired resistance, specifically, can result from mutation or acquisition of exogenous resistance determinants and can be mediated by a number of mechanisms, including degrading enzymes, reduced permeability, and active efflux [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/42,54\" class=\"abstract_t\">42,54</a>]. </p><p>With respect to degrading enzymes, plasmid-mediated extended spectrum beta-lactamases (ESBLs) have been described at a limited number of geographic sites. TEM, SHV, and CTX-M ESBLs have been reported in <em>P. aeruginosa</em>, but are uncommon; VEB ESBLs are prevalent in the species in East Asia and are now scattered elsewhere, and PER types are widespread in Turkey. These enzymes confer high-level resistance to antipseudomonal cephalosporins, and some, such as PER-1, also degrade cephems and monobactams [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">&quot;Extended-spectrum beta-lactamases&quot;</a>.)</p><p>The potential impact of PER-1 was illustrated in a series of 26 <em>P. aeruginosa</em> bloodstream infections (BSIs) from Siena, Italy [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/42\" class=\"abstract_t\">42</a>]. Nine expressed PER-1 and the other 17 did not express any ESBL. Seven of the nine PER-1 BSIs failed to respond to antibiotic therapy, including carbapenems. In comparison, only 4 of 14 non-ESBL BSIs failed to respond, including only one of eight treated with a carbapenem.</p><p>Resistance to carbapenems, particularly <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>, can arise by simple mutation resulting in the loss of a carbapenem-specific porin, OprD [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/43\" class=\"abstract_t\">43</a>]. Less often, metallo-beta-lactamases (MBLs) are responsible: VIM and IMP MBLs have been reported internationally, whereas clones with SPM-1 enzymes have disseminated in Brazil. Some have caused major outbreaks, with dozens to hundreds of patients affected over prolonged periods. (See <a href=\"topic.htm?path=overview-of-carbapenemase-producing-gram-negative-bacilli\" class=\"medical medical_review\">&quot;Overview of carbapenemase-producing gram-negative bacilli&quot;</a>.)</p><p>Multidrug resistance in <em>P. aeruginosa </em>is believed to be secondary to efflux pumps on the bacterial surface. One study demonstrated that the addition of an efflux inhibitor in vitro decreased the MICs of <em>P. aeruginosa </em>isolates to various antibiotics by twofold or more [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/55\" class=\"abstract_t\">55</a>]. </p><p class=\"headingAnchor\" id=\"H1590804377\"><span class=\"h2\">Prevalence of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patterns of antibiotic resistance in <em>P. aeruginosa</em> evolve over time and vary geographically and by type of infection. This geographical variation highlights the importance of local epidemiological data when choosing empiric therapy. </p><p>As an example, in North America from 2005 to 2010, resistance to fluoroquinolones among intra-abdominal and urinary tract infection isolates increased (from 22 to 33 percent), resistance to <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> (20 percent) and other beta-lactams (<a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a>, <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>, and <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>; 23 to 26 percent) remained essentially unchanged, and resistance to <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a> declined (from 11 to 3 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/7\" class=\"abstract_t\">7</a>]. Resistance patterns were different in other locations: in South Africa, resistance to piperacillin-tazobactam was 8 percent and to cefepime, ceftazidime, and imipenem was 25 to 26 percent; in China, resistance rates to amikacin and piperacillin-tazobactam were 12 and 8 percent, respectively. </p><p>In the United States specifically, surveillance suggests a trend towards declining rates of resistance, although rates still remain high [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/6\" class=\"abstract_t\">6</a>]. Among catheter-related bloodstream infection, catheter-associated urinary tract infection, and ventilator associated pneumonia isolates, resistance ranged from 22 to 26 percent for extended-spectrum cephalosporins, 16 to 19 for <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a>, 30 to 33 percent for fluoroquinolones, 24 to 28 percent for carbapenems, and 17 to 23 percent for aminoglycosides. Approximately 18 to 19 percent were multidrug-resistant. Rates of resistance were generally lower (4 to 11 percent) among surgical site infection isolates. </p><p>The use of locally-derived antibiograms to predict susceptibility of individual antibiotics to <em>P. aeruginosa</em> may not be as reliable for patients who become infected during long hospital stays. In one study involving 3393 isolates of <em>P. aeruginosa</em> from a single tertiary care hospital, the utility of the hospital&rsquo;s antibiogram dropped as the length of time from admission to recovery of <em>P. aeruginosa</em> increased [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/56\" class=\"abstract_t\">56</a>].</p><p>Better ways of administering antibiotics have been considered to overcome the increasing resistance patterns. In a pharmacodynamic analysis, high-dose, prolonged infusions of <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>, <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, <a href=\"topic.htm?path=doripenem-drug-information\" class=\"drug drug_general\">doripenem</a>, and <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> had the highest probabilities of achieving bactericidal exposure for <em>P. aeruginosa </em>[<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Prolonged infusions of beta-lactam antibiotics&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individual strains may contain a large number of virulence factors: more than those encountered in other pathogens, such as group A streptococcus and <em>Staphylococcus aureus</em>. <em>P. aeruginosa</em> is capable of elaborating a large number of toxins and surface components associated with virulence [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/58-60\" class=\"abstract_t\">58-60</a>]. While each of these toxins and surface components may show a deleterious effect in cell lines or even in an animal model, the role of many of these putative virulence factors remains unproven in humans. </p><p>In contrast to most other bacteria, <em>P. aeruginosa</em> has two modes of virulence expression, resulting in at least two forms of distinct pathogenetic behavior:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It can remain confined to the lungs as a chronic, indolent colonizer (as occurs in many patients with cystic fibrosis [CF])</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It can invade tissues, causing pneumonia or bacteremia along with their potential complications of septic shock and death</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Chronic infection in cystic fibrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies that have serially examined both the bacterial diversity and load of the microbial flora in the lower respiratory tract of patients with CF have demonstrated that bacterial diversity typically decreases as the severity of illness increases even though the total bacterial load remains relatively stable [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/61\" class=\"abstract_t\">61</a>]. <em>P. aeruginosa</em> is present as part of the resident microbial flora in the lower respiratory tract of most patients with CF, and in some patients, <em>P. aeruginosa</em> becomes the dominant organism as the severity of CF illness progresses. </p><p>Most patients with CF eventually die from respiratory failure because of a gradual loss of lung function. This loss of function is a consequence of decades of continuous colonization with <em>P. aeruginosa</em> and inflammation triggered by the host response to the organism [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/62\" class=\"abstract_t\">62</a>]. It may be argued that there is no expression of virulence in this setting and that the inflammation is simply a bystander reaction by the host to the presence of an organism in the airways. However, the fact that <em>P. aeruginosa</em> persists in the airways to the exclusion of most other bacteria suggests there is active expression of specific genes to maintain this tropism. (See <a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease#H1531054\" class=\"medical medical_review\">&quot;Cystic fibrosis: Clinical manifestations of pulmonary disease&quot;, section on 'Pathogens'</a>.)</p><p>A detailed, whole-genome analysis of <em>P. aeruginosa</em> isolates from a CF patient during eight years of infection found that virulence factors that are required for the initiation of acute infections are selected against during subsequent chronic infection [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/63\" class=\"abstract_t\">63</a>]. </p><p class=\"headingAnchor\" id=\"H784419753\"><span class=\"h3\">Early airway colonization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are at least three possible mechanisms allowing early airway colonization with <em>P. aeruginosa</em> in patients with CF:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following initial acquisition, the organism has a propensity to attach to cells via pili and flagella, resulting in an initial infection [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/64\" class=\"abstract_t\">64</a>]. This hypothesis suggests that there are more pilus receptors on CF cells or that there is a greater response to pilin binding than on normal airway cells [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/65\" class=\"abstract_t\">65</a>]. Piliated organisms or purified pili lead to the production of interleukin-8 on airway epithelial cells; in one study, this response was four times higher in a CF cell line [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The cystic fibrosis transmembrane conductance regulator (CFTR) may function as a cellular receptor for <em>P. aeruginosa </em>that<em> </em>facilitates phagocytosis and clearance of the organism from the airways. Patients with CF may lack CFTR or express a mutant CFTR that prevents phagocytosis and clearance from the airway. In an in vitro study, murine cells expressing recombinant human wild-type CFTR ingested 30 to 100 times as many <em>P. aeruginosa</em> organisms as cells lacking CFTR or those expressing the mutant delta F508 CFTR protein seen in CF [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/66\" class=\"abstract_t\">66</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The airways of patients with CF commonly manifest mucous hypersecretion and a defect in mucociliary clearance that progressively worsens with age; <em>P. aeruginosa</em> is able to bind to mucous in airways and thus is protected from phagocytosis [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/67,68\" class=\"abstract_t\">67,68</a>].</p><p/><p>There is no animal model of chronic lung colonization to study the relative importance and quantitative aspects of the above three mechanisms.</p><p>Of note, some studies have observed that the isolates in CF patients with newly identified <em>P. aeruginosa</em> infection frequently have mucoid- and biofilm-forming phenotypes, which are more classically associated with adaptation towards chronic persistence in the CF lung [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/69,70\" class=\"abstract_t\">69,70</a>]. (See <a href=\"#H9\" class=\"local\">'Persistence of the organism in the airways'</a> below.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Persistence of the organism in the airways</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An examination of <em>P. aeruginosa</em> organisms isolated from this chronic state of colonization in patients with CF frequently shows the following abnormalities:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Downregulation of the production of toxins [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/71\" class=\"abstract_t\">71</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Loss of lipopolysaccharides &quot;O&quot; side chains [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/72\" class=\"abstract_t\">72</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Expression of an alginate coat that probably protects against phagocytosis [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/73,74\" class=\"abstract_t\">73,74</a>] (see <a href=\"#H9635378\" class=\"local\">'Mucoid phenotype'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Frequent loss of the flagellum and pili [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/75,76\" class=\"abstract_t\">75,76</a>]</p><p/><p>Conventional wisdom about pathogenesis states that pathogens produce diseases by expressing their virulence factors. There are two possible explanations for this observed downregulation of virulence factors:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The immunologic response to virulence factors within colonizing strains of <em>P. aeruginosa</em> selects for survival of those strains that have mutated to phenotypes that evade the host immune mechanisms in the lungs. The observation that <em>P. aeruginosa</em> flagellin synthesis is downregulated in the CF lung could represent an adaptive response by the organism to avoid detection by host defense mechanisms, as flagellin is highly immunogenic and subject to detection by host pattern recognition receptors [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/77\" class=\"abstract_t\">77</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Virulence factors may no longer be needed for chronic colonization, and they disappear from strains colonizing the airways because of random mutations in the genes responsible for their expression.</p><p/><p>Although mutations such as those discussed above could explain why host defenses do not eradicate the organisms, it is probable that organisms with a normal phenotype are able to persist in the face of intact host defense mechanisms early in the life of many patients with CF. Thus, the best explanation for persistence may be defects in mucociliary clearance and in host killing of bacteria in CF.</p><p class=\"headingAnchor\" id=\"H9635348\"><span class=\"h4\">Decreased bacterial killing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of studies have suggested that the lungs of patients with CF have defective mechanisms for bacterial killing. This may be related in part to the high chloride concentrations in pulmonary secretions [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/78\" class=\"abstract_t\">78</a>]. Defects in bacterial killing induced by a high chloride environment include inactivation of beta-defensins, which are antimicrobial peptides secreted by respiratory epithelia [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/79,80\" class=\"abstract_t\">79,80</a>], increased release of inflammatory mediators by neutrophils, and diminished neutrophil killing [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/81\" class=\"abstract_t\">81</a>].</p><p>However, such defects in patients with CF do not explain the preferential selection of <em>P. aeruginosa</em> as a pathogen over other bacteria. The predisposition to <em>Pseudomonas </em>infection in patients with CF may be due in part to impaired clearance directly related to defects in CFTR discussed above [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/66,82\" class=\"abstract_t\">66,82</a>]. For example, treatment with <a href=\"topic.htm?path=ivacaftor-drug-information\" class=\"drug drug_general\">ivacaftor</a>, which restores functioning of the CFTR protein, is associated with reduced <em>P. aeruginosa</em> culture positivity [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/83\" class=\"abstract_t\">83</a>]. Similarly, CFTR-knockout mice have an impaired ability to control pseudomonas lung infections characterized by increased binding of <em>P. aeruginosa</em> to respiratory epithelial cells, an effect that can be reversed by CFTR gene transfer [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/84,85\" class=\"abstract_t\">84,85</a>].</p><p class=\"headingAnchor\" id=\"H9635371\"><span class=\"h4\">Biofilm formation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biofilm or microcolony formation in <em>P. aeruginosa</em> may also facilitate the ability of this organism to persist in the airways of patients with CF. Organisms contained in biofilms are resistant to antibiotic treatment, which in turn facilitates persistence in airways. As an example, in a study of CF patients with newly identified <em>P. aeruginosa</em> airway infection, wrinkly colony surface and irregular colony edges (phenotypes previously implicated in increased biofilm formation and aberrant quorum sensing) were associated with persistence following antibiotic treatment [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/69\" class=\"abstract_t\">69</a>].</p><p>An in vitro study of <em>P. aeruginosa</em> identified that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/86\" class=\"abstract_t\">86</a>]. A <em>P. aeruginosa</em> gene (aminoglycoside response regulator [arr]) was essential for this induction and contributed to biofilm-specific aminoglycoside resistance. Biofilm formation can be a specific, defensive reaction to the presence of antibiotics: a mechanism that may be responsible for the differences in therapeutic outcome in CF patients treated with <a href=\"topic.htm?path=tobramycin-drug-information\" class=\"drug drug_general\">tobramycin</a> aerosols. (See <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9635378\"><span class=\"h4\">Mucoid phenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During prolonged colonization, <em>P. aeruginosa</em> isolates often convert to a mucoid phenotype through production of the polysaccharide alginate (<a href=\"image.htm?imageKey=ID%2F56963\" class=\"graphic graphic_picture graphicRef56963 \">picture 2</a>). Alginate production contributes to biofilm growth, decreased clearance by host immune responses, and tissue damage [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/87\" class=\"abstract_t\">87</a>]. One study demonstrated that alginate production was increased when the organisms were present in the relatively anaerobic environment of CF mucous [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/88\" class=\"abstract_t\">88</a>]. This mucoid phenotype is seen infrequently in non-CF populations, but occurs in over 75 percent of <em>P. aeruginosa</em> isolated from patients with CF. Opsonic antibodies produced by the host in CF are unable to kill these mucoid organisms [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/89\" class=\"abstract_t\">89</a>]. (See <a href=\"topic.htm?path=cystic-fibrosis-genetics-and-pathogenesis\" class=\"medical medical_review\">&quot;Cystic fibrosis: Genetics and pathogenesis&quot;</a>.)</p><p>Among patients with CF, women are colonized with mucoid <em>P. aeruginosa</em> more frequently and earlier in chronic infection than men. Estrogen production appears to be directly related to this finding, as illustrated by a study in which exposure to estrogens induced alginate production in a nonmucoid strain of <em>P. aeruginosa</em> in vitro [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/90\" class=\"abstract_t\">90</a>]. In vivo, mucoid strains of <em>P. aeruginosa</em> were isolated more frequently during times of high estradiol production in six women with CF who were sampled throughout their menstrual cycles. Furthermore, among 23 women, mucoid <em>P. aeruginosa</em> accounted for 63 percent of strains isolated from pulmonary CF exacerbations that occurred during the follicular (high estradiol) phase of the menstrual cycle. In contrast, no strains isolated from exacerbations during the luteal phase (low estradiol) had the mucoid phenotype. Pulmonary exacerbations were also observed more frequently during the follicular phase. </p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Promotion of S. aureus colonization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> may also promote <em>S. aureus</em> colonization in the CF lung. An exoproduct of <em>P. aeruginosa</em> (HQNO) protects <em>S. aureus</em> from killing by aminoglycosides and selects for small-colony variants of <em>S. aureus</em> that have stable aminoglycoside resistance and persist in chronic infection [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/91\" class=\"abstract_t\">91</a>]. HQNO can be detected in the sputum of CF patients infected with <em>P. aeruginosa</em> but not in uninfected patients. (See <a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease#H2\" class=\"medical medical_review\">&quot;Cystic fibrosis: Clinical manifestations of pulmonary disease&quot;, section on 'Progression of pulmonary disease'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Acute invasive P. aeruginosa infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> possesses an array of virulence factors implicated in acute infections [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/92\" class=\"abstract_t\">92</a>]. These include secreted products, exotoxins A, S, and U, elastase, alkaline protease, cytotoxins, phospholipase C, and phenazines [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/93-95\" class=\"abstract_t\">93-95</a>]. Cell-bound organelles (such as pili and flagella) and membrane-bound lipopolysaccharide (LPS, endotoxin) have also been implicated in virulence.</p><p>There is no single product that explains the organism's ability to cause disease and death, especially since it is an opportunistic pathogen whose virulence is expressed mainly in the immunocompromised host. A reasonable synthesis of the experimental work in this area is that different virulence factors play a role at different stages in the pathogenesis of invasive infections.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Invasion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa </em>requires an intact flagellum and motility to exert its maximum invasive effect in some animal models of infection. Strains lacking flagella are less capable of causing bacteremia and pneumonia in neonatal mice [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/96\" class=\"abstract_t\">96</a>] and of disseminating from burn wounds [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/97,98\" class=\"abstract_t\">97,98</a>].</p><p>The relative importance of the motility function of flagellum and a possible proinflammatory role of flagellin were examined in a lung model of acute <em>P. aeruginosa</em> infection [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/99\" class=\"abstract_t\">99</a>]. The findings suggested that flagellin is involved in early mortality, while loss of motility alone did not appear to affect virulence. Thus, the decreased virulence in strains lacking flagella in the neonatal mouse model cited above is more likely due to the absence of flagellin [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/96\" class=\"abstract_t\">96</a>]. (See <a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa pneumonia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Lipopolysaccharide and toxins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After invasion, LPS probably plays a role in disease similar to that proposed for other gram-negative pathogens. LPS protects the organism from the activity of complement in the bloodstream and triggers cytokine pathways, leading to sepsis and septic shock. (See <a href=\"topic.htm?path=pathophysiology-of-sepsis\" class=\"medical medical_review\">&quot;Pathophysiology of sepsis&quot;</a>.)</p><p>In addition to LPS, it has been proposed that the elaboration of toxins after invasion is responsible for some of the tissue damage. The role of toxins in the disease process has been difficult to determine, as there are no data incriminating a specific toxin, such as is found with diphtheria toxin or the staphylococcal and streptococcal shock toxins. In addition, mutants of <em>P. aeruginosa</em> lacking many of these toxins remain virulent.</p><p>Thus, although toxins are probably not needed for the major disease syndromes encountered in most patients with <em>P. aeruginosa</em> infections, they may play a role in some localized infections, such as in the eye [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/100\" class=\"abstract_t\">100</a>] or lung [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/84,101\" class=\"abstract_t\">84,101</a>], and contribute to the severity of disease. This potential effect was illustrated in a study of <em>P. aeruginosa</em> strains isolated from 108 consecutive patients with lower respiratory or systemic infection [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/101\" class=\"abstract_t\">101</a>]. Infection with <em>a P. aeruginosa</em> strain expressing the type III secreted toxins (eg, ExoS, ExoT, ExoU, or PcrV) was associated with a sixfold greater risk of death compared with infection with a strain that did not express these proteins (odds ratio, 6.2; 95% CI, 1.2-31.1). Expression of these toxins is associated with higher mortality in patients with <em>P. aeruginosa</em> bacteremia as well [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/85\" class=\"abstract_t\">85</a>]. </p><p>The degree of infection may be limited by host factors. Experimental data suggest that host ubiquitin ligase Cbl-b limits <em>P. aeruginosa</em> dissemination mediated by the secreted toxin ExoT [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/102\" class=\"abstract_t\">102</a>]. Ubiquitination leads to proteasomal degradation of the toxin.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Potential for vaccine therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Part of the impetus for studies of pathogenesis in <em>P. aeruginosa</em> infections is interest in the development of a vaccine to prevent infection in susceptible hosts or new antimicrobials for treatment of the organism. At present, no vaccines or specific antibiotics have resulted from this work, but development of vaccines against type III secretion system proteins [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/103\" class=\"abstract_t\">103</a>], as well as LPS [<a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/104\" class=\"abstract_t\">104</a>], continues. The <em>Pseudomonas</em> genome sequence should provide further insights into the mechanisms of pathogenesis of <em>P. aeruginosa</em> infections and suggest new targets that can be exploited for vaccine development.</p><p class=\"headingAnchor\" id=\"H19299002\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Pseudomonas aeruginosa</em>, a nonfermenting gram-negative bacillus, is prevalent in the environment, particularly in water, which can serve as a reservoir for infection. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain features are characteristic of <em>P. aeruginosa</em> grown on culture and help confirm its identification. These include a sweet grape-like odor, elaboration of green pigment, and oxidase-positivity. (See <a href=\"#H20477480\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> is a common cause of nosocomial pneumonia, urinary tract infection, and surgical site infection. It has become a less frequent cause of bacteremia in patients with neutropenia in most parts of the world. It remains the most important pathogen in patients with cystic fibrosis. <em>P. aeruginosa</em> is also associated with certain community-acquired infections following particular exposures (eg, water, puncture wounds, injection drug use). (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with cystic fibrosis, chronic colonization with <em>P. aeruginosa</em> is associated with a downregulation of virulence factors and expression of a mucoid phenotype that likely protects against phagocytosis and opsonization. <em>P. aeruginosa</em> may also promote <em>Staphylococcus aureus</em> colonization in the lungs of patients with cystic fibrosis. (See <a href=\"#H8\" class=\"local\">'Chronic infection in cystic fibrosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strains that cause acute infections express a wide array of virulence factors. These include an intact flagellum, lipopolysaccharide, and secreted toxins. (See <a href=\"#H12\" class=\"local\">'Acute invasive P. aeruginosa infections'</a> above.).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>P. aeruginosa</em> can develop resistance to antibiotics through a number of mechanisms, including expression of a beta-lactamase or efflux pumps and downregulation of outer membrane porins. (See <a href=\"#H1864320089\" class=\"local\">'Antimicrobial resistance'</a> above.) </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/1\" class=\"nounderline abstract_t\">Warburton DW, Bowen B, Konkle A. The survival and recovery of Pseudomonas aeruginosa and its effect upon salmonellae in water: methodology to test bottled water in Canada. Can J Microbiol 1994; 40:987.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/2\" class=\"nounderline abstract_t\">Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science 1971; 173:836.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/3\" class=\"nounderline abstract_t\">Silverman AR, Nieland ML. Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis. J Am Acad Dermatol 1983; 8:153.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/4\" class=\"nounderline abstract_t\">Wilson LA, Schlitzer RL, Ahearn DG. Pseudomonas corneal ulcers associated with soft contact-lens wear. Am J Ophthalmol 1981; 92:546.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/5\" class=\"nounderline abstract_t\">Labarca JA, Pegues DA, Wagar EA, et al. Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa. Clin Infect Dis 1998; 26:1440.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/6\" class=\"nounderline abstract_t\">Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/7\" class=\"nounderline abstract_t\">Morrissey I, Hackel M, Badal R, et al. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013; 6:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/8\" class=\"nounderline abstract_t\">Wang L, Wang Y, Fan X, et al. Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study. Medicine (Baltimore) 2015; 94:e1931.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/9\" class=\"nounderline abstract_t\">Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med 1998; 37:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/10\" class=\"nounderline abstract_t\">Gudiol C, Royo-Cebrecos C, Laporte J, et al. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirology 2016; 21:1411.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/11\" class=\"nounderline abstract_t\">Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am 2016; 63:567.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/12\" class=\"nounderline abstract_t\">Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/13\" class=\"nounderline abstract_t\">Salsgiver EL, Fink AK, Knapp EA, et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 2016; 149:390.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/14\" class=\"nounderline abstract_t\">Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998; 26:81.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/15\" class=\"nounderline abstract_t\">Renders NH, Sijmons MA, van Belkum A, et al. Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol 1997; 148:447.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/16\" class=\"nounderline abstract_t\">Oliver A, Cant&oacute;n R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/17\" class=\"nounderline abstract_t\">Hogardt M, Hoboth C, Schmoldt S, et al. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007; 195:70.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/18\" class=\"nounderline abstract_t\">Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/19\" class=\"nounderline abstract_t\">Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/20\" class=\"nounderline abstract_t\">Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/21\" class=\"nounderline abstract_t\">Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/22\" class=\"nounderline abstract_t\">Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/23\" class=\"nounderline abstract_t\">Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/24\" class=\"nounderline abstract_t\">Iversen BG, Jacobsen T, Eriksen HM, et al. An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs. Clin Infect Dis 2007; 44:794.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/25\" class=\"nounderline abstract_t\">Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/26\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa respiratory tract infections associated with contaminated ultrasound gel used for transesophageal echocardiography - Michigan, December 2011-January 2012. MMWR Morb Mortal Wkly Rep 2012; 61:262.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/27\" class=\"nounderline abstract_t\">Hallin M, Deplano A, Roisin S, et al. Pseudo-outbreak of extremely drug-resistant pseudomonas aeruginosa urinary tract infections due to contamination of an automated urine analyzer. J Clin Microbiol 2012; 50:580.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/28\" class=\"nounderline abstract_t\">Ratnam S, Hogan K, March SB, Butler RW. Whirlpool-associated folliculitis caused by Pseudomonas aeruginosa: report of an outbreak and review. J Clin Microbiol 1986; 23:655.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/29\" class=\"nounderline abstract_t\">Maniatis AN, Karkavitsas C, Maniatis NA, et al. Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Clin Infect Dis 1995; 21:437.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/30\" class=\"nounderline abstract_t\">Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/31\" class=\"nounderline abstract_t\">Dixon RS, Sydnor CH 4th. Puncture wound pseudomonal osteomyelitis of the foot. J Foot Ankle Surg 1993; 32:434.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/32\" class=\"nounderline abstract_t\">Silverman NA, Levitsky S, Mammana R. Acute endocarditis in drug addicts: surgical treatment for multiple valve infection. J Am Coll Cardiol 1984; 4:680.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/33\" class=\"nounderline abstract_t\">Shekar R, Rice TW, Zierdt CH, Kallick CA. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis 1985; 151:203.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/34\" class=\"nounderline abstract_t\">van Asperen IA, de Rover CM, Schijven JF, et al. Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. BMJ 1995; 311:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/35\" class=\"nounderline abstract_t\">Chan MK, Chan PC, Cheng IP, et al. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment. Nephrol Dial Transplant 1989; 4:814.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/36\" class=\"nounderline abstract_t\">Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2:1498.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/37\" class=\"nounderline abstract_t\">Lo CY, Chu WL, Wan KM, et al. Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment. Perit Dial Int 1998; 18:637.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/38\" class=\"nounderline abstract_t\">Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis 1993; 148:992.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/39\" class=\"nounderline abstract_t\">Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/40\" class=\"nounderline abstract_t\">Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36:2046.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/41\" class=\"nounderline abstract_t\">Masuda N, Gotoh N, Ishii C, et al. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:400.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/42\" class=\"nounderline abstract_t\">Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/43\" class=\"nounderline abstract_t\">Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1:i29.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/44\" class=\"nounderline abstract_t\">Pai H, Kim J, Kim J, et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45:480.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/45\" class=\"nounderline abstract_t\">K&ouml;hler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/46\" class=\"nounderline abstract_t\">Aires JR, K&ouml;hler T, Nikaido H, Pl&eacute;siat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999; 43:2624.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/47\" class=\"nounderline abstract_t\">De Kievit TR, Parkins MD, Gillis RJ, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45:1761.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/48\" class=\"nounderline abstract_t\">Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003; 47:3202.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/49\" class=\"nounderline abstract_t\">Hocquet D, Bertrand X, K&ouml;hler T, et al. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003; 47:1887.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/50\" class=\"nounderline abstract_t\">Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/51\" class=\"nounderline abstract_t\">Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/52\" class=\"nounderline abstract_t\">Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426:306.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/53\" class=\"nounderline abstract_t\">Yokoyama K, Doi Y, Yamane K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003; 362:1888.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/54\" class=\"nounderline abstract_t\">Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11 Suppl 4:17.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/55\" class=\"nounderline abstract_t\">Talebi-Taher M, Majidpour &#1614;, Gholami A, et al. Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran. J Infect Dev Ctries 2016; 10:600.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/56\" class=\"nounderline abstract_t\">Anderson DJ, Miller B, Marfatia R, Drew R. Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation. Infect Control Hosp Epidemiol 2012; 33:589.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/57\" class=\"nounderline abstract_t\">Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32:766.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/58\" class=\"nounderline abstract_t\">Pollack M, Taylor NS, Callahan LT 3rd. Exotoxin production by clinical isolates of pseudomonas aeruginosa. Infect Immun 1977; 15:776.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/59\" class=\"nounderline abstract_t\">Somerville G, Mikoryak CA, Reitzer L. Physiological characterization of Pseudomonas aeruginosa during exotoxin A synthesis: glutamate, iron limitation, and aconitase activity. J Bacteriol 1999; 181:1072.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/60\" class=\"nounderline abstract_t\">Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40:615.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/61\" class=\"nounderline abstract_t\">Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012; 109:5809.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/62\" class=\"nounderline abstract_t\">Fick RB Jr, Sonoda F, Hornick DB. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Semin Respir Infect 1992; 7:168.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/63\" class=\"nounderline abstract_t\">Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006; 103:8487.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/64\" class=\"nounderline abstract_t\">DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995; 96:2204.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/65\" class=\"nounderline abstract_t\">Cervin MA, Simpson DA, Smith AL, Lory S. Differences in eucaryotic cell binding of Pseudomonas. Microb Pathog 1994; 17:291.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/66\" class=\"nounderline abstract_t\">Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997; 94:12088.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/67\" class=\"nounderline abstract_t\">Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984; 45:197.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/68\" class=\"nounderline abstract_t\">Vishwanath S, Ramphal R, Guay CM, et al. Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa. Infect Immun 1988; 56:2218.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/69\" class=\"nounderline abstract_t\">Mayer-Hamblett N, Ramsey BW, Kulasekara HD, et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis 2014; 59:624.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/70\" class=\"nounderline abstract_t\">Manos J, Hu H, Rose BR, et al. Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2013; 32:1583.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/71\" class=\"nounderline abstract_t\">Raivio TL, Ujack EE, Rabin HR, Storey DG. Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients. Infect Immun 1994; 62:3506.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/72\" class=\"nounderline abstract_t\">Hancock RE, Mutharia LM, Chan L, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983; 42:170.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/73\" class=\"nounderline abstract_t\">Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145 ( Pt 6):1349.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/74\" class=\"nounderline abstract_t\">Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997; 65:3838.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/75\" class=\"nounderline abstract_t\">Pier GB, Meluleni G, Neuger E. A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun 1992; 60:4768.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/76\" class=\"nounderline abstract_t\">Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/77\" class=\"nounderline abstract_t\">Wolfgang MC, Jyot J, Goodman AL, et al. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A 2004; 101:6664.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/78\" class=\"nounderline abstract_t\">Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/79\" class=\"nounderline abstract_t\">Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88:553.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/80\" class=\"nounderline abstract_t\">Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102:874.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/81\" class=\"nounderline abstract_t\">Tager AM, Wu J, Vermeulen MW. The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis. Am J Respir Cell Mol Biol 1998; 19:643.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/82\" class=\"nounderline abstract_t\">Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271:64.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/83\" class=\"nounderline abstract_t\">Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60:703.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/84\" class=\"nounderline abstract_t\">Finck-Barban&ccedil;on V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/85\" class=\"nounderline abstract_t\">El-Solh AA, Hattemer A, Hauser AR, et al. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/86\" class=\"nounderline abstract_t\">Hoffman LR, D'Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/87\" class=\"nounderline abstract_t\">Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003; 52:731.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/88\" class=\"nounderline abstract_t\">Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/89\" class=\"nounderline abstract_t\">Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995; 155:2029.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/90\" class=\"nounderline abstract_t\">Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012; 366:1978.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/91\" class=\"nounderline abstract_t\">Hoffman LR, D&eacute;ziel E, D'Argenio DA, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2006; 103:19890.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/92\" class=\"nounderline abstract_t\">Tan MW, Rahme LG, Sternberg JA, et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A 1999; 96:2408.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/93\" class=\"nounderline abstract_t\">Mahajan-Miklos S, Tan MW, Rahme LG, Ausubel FM. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell 1999; 96:47.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/94\" class=\"nounderline abstract_t\">Kamath S, Kapatral V, Chakrabarty AM. Cellular function of elastase in Pseudomonas aeruginosa: role in the cleavage of nucleoside diphosphate kinase and in alginate synthesis. Mol Microbiol 1998; 30:933.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/95\" class=\"nounderline abstract_t\">Matsumoto T, Tateda K, Furuya N, et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 1998; 47:303.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/96\" class=\"nounderline abstract_t\">Feldman M, Bryan R, Rajan S, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998; 66:43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/97\" class=\"nounderline abstract_t\">Drake D, Montie TC. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J Gen Microbiol 1988; 134:43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/98\" class=\"nounderline abstract_t\">Arora SK, Neely AN, Blair B, et al. Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections. Infect Immun 2005; 73:4395.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/99\" class=\"nounderline abstract_t\">Balloy V, Verma A, Kuravi S, et al. The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 2007; 196:289.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/100\" class=\"nounderline abstract_t\">Fleiszig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun 1996; 64:2288.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/101\" class=\"nounderline abstract_t\">Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/102\" class=\"nounderline abstract_t\">Balachandran P, Dragone L, Garrity-Ryan L, et al. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J Clin Invest 2007; 117:419.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/103\" class=\"nounderline abstract_t\">Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection/abstract/104\" class=\"nounderline abstract_t\">DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004; 72:7012.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3142 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H19299002\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H20477480\" id=\"outline-link-H20477480\">MICROBIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Neutropenia and burns</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Cystic fibrosis</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Other nosocomial infections</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Community-acquired infections</a></li></ul></li><li><a href=\"#H1864320089\" id=\"outline-link-H1864320089\">ANTIMICROBIAL RESISTANCE</a><ul><li><a href=\"#H340045430\" id=\"outline-link-H340045430\">Mechanisms of resistance</a></li><li><a href=\"#H1590804377\" id=\"outline-link-H1590804377\">Prevalence of resistance</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PATHOGENESIS</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Chronic infection in cystic fibrosis</a><ul><li><a href=\"#H784419753\" id=\"outline-link-H784419753\">- Early airway colonization</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Persistence of the organism in the airways</a><ul><li><a href=\"#H9635348\" id=\"outline-link-H9635348\">Decreased bacterial killing</a></li><li><a href=\"#H9635371\" id=\"outline-link-H9635371\">Biofilm formation</a></li><li><a href=\"#H9635378\" id=\"outline-link-H9635378\">Mucoid phenotype</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Promotion of S. aureus colonization</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">Acute invasive P. aeruginosa infections</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Invasion</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Lipopolysaccharide and toxins</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Potential for vaccine therapy</a></li></ul></li><li><a href=\"#H19299002\" id=\"outline-link-H19299002\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3142|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/77055\" class=\"graphic graphic_picture\">- Pigment from Pseudomonas aeruginosa</a></li><li><a href=\"image.htm?imageKey=ID/56963\" class=\"graphic graphic_picture\">- Pseudomonas aeruginosa on MacConkey agar</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-unexplained-neutropenia\" class=\"medical medical_review\">Approach to the adult with unexplained neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease\" class=\"medical medical_review\">Cystic fibrosis: Clinical manifestations of pulmonary disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-genetics-and-pathogenesis\" class=\"medical medical_review\">Cystic fibrosis: Genetics and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-neutropenia-and-agranulocytosis\" class=\"medical medical_review\">Drug-induced neutropenia and agranulocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">Extended-spectrum beta-lactamases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-general-principles\" class=\"medical medical_review\">Infection prevention: General principles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-carbapenemase-producing-gram-negative-bacilli\" class=\"medical medical_review\">Overview of carbapenemase-producing gram-negative bacilli</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neutropenia-in-children-and-adolescents\" class=\"medical medical_review\">Overview of neutropenia in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-sepsis\" class=\"medical medical_review\">Pathophysiology of sepsis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">Prolonged infusions of beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-bacteremia-and-endocarditis\" class=\"medical medical_review\">Pseudomonas aeruginosa bacteremia and endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">Pseudomonas aeruginosa pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">Pseudomonas aeruginosa skin and soft tissue infections</a></li></ul></div></div>","javascript":null}